BRPI0606481A2 - composição de vacina compreendendo uma proteìna de ligação a fibronectina ou um peptìdeo de ligação a fibronectina - Google Patents
composição de vacina compreendendo uma proteìna de ligação a fibronectina ou um peptìdeo de ligação a fibronectinaInfo
- Publication number
- BRPI0606481A2 BRPI0606481A2 BRPI0606481-7A BRPI0606481A BRPI0606481A2 BR PI0606481 A2 BRPI0606481 A2 BR PI0606481A2 BR PI0606481 A BRPI0606481 A BR PI0606481A BR PI0606481 A2 BRPI0606481 A2 BR PI0606481A2
- Authority
- BR
- Brazil
- Prior art keywords
- fibronectin
- fibronectin binding
- binding
- binding protein
- relates
- Prior art date
Links
- 102000016359 Fibronectins Human genes 0.000 title abstract 7
- 108010067306 Fibronectins Proteins 0.000 title abstract 7
- 101000815632 Streptococcus suis (strain 05ZYH33) Rqc2 homolog RqcH Proteins 0.000 title abstract 5
- 102000036072 fibronectin binding proteins Human genes 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 239000011159 matrix material Substances 0.000 abstract 3
- 150000002632 lipids Chemical class 0.000 abstract 2
- 239000002502 liposome Substances 0.000 abstract 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 2
- 229930182490 saponin Natural products 0.000 abstract 2
- 150000007949 saponins Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
COMPOSIçãO DE VACINA COMPREENDENDO UMA. PROTEìNA DE LIGAçãO A FIBRONECTINA OU UM PEPTìDEO DE LIGAçãO A FIBRONECTINA. A presente invenção refere-se a uma composição compreendendo pelo menos uma proteína de ligação a fibronectina, e/ou pelo menos uma proteína de ligação a fibronectina truncada e/ou pelo menos um peptídeo de ligação a fibronectina, todos compreendendo pelo menos um domínio de ligação a fibronectina; e pelo menos um complexo de matriz de iscom e/ou lipossoma e/ou pelo menos um lipídeo e pelo menos uma saponina, pelo que o pelo menos um lipídeo e a pelo menos uma saponina podem estar complexados, em solução ou suspensão. Além disto, refere-se ao uso da composição para a produção de uma vacina contra um microrganismo que compreende pelo menos um domínio de ligação a fibronectína. Refere-se também a um kit compreendendo pelo menos dois compartimentos, onde um compartimento compreende pelo menos uma proteína de ligação a fíbronectina truncada e/ou um peptídeo de ligação a fíbronectina, que compreende pelo menos um domínio de ligação a fibronectina, e um outro compartimento que compreende uma instrução para uso e/ou um complexo de matriz de iscom e/ou um complexo de matriz de iscom e/ou um lipossoma. Refere-se ainda a um método para vacinação de um indivíduo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59350405P | 2005-01-20 | 2005-01-20 | |
| PCT/SE2006/000082 WO2006078213A1 (en) | 2005-01-20 | 2006-01-20 | Vaccine composition comprisinga fibronectin binding protein or a fibronectin binding peptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0606481A2 true BRPI0606481A2 (pt) | 2009-06-30 |
Family
ID=36692518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0606481-7A BRPI0606481A2 (pt) | 2005-01-20 | 2006-01-20 | composição de vacina compreendendo uma proteìna de ligação a fibronectina ou um peptìdeo de ligação a fibronectina |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8007806B2 (pt) |
| EP (1) | EP1838341B1 (pt) |
| CN (1) | CN101107009B (pt) |
| BR (1) | BRPI0606481A2 (pt) |
| CA (1) | CA2592627C (pt) |
| DK (1) | DK1838341T3 (pt) |
| ES (1) | ES2433467T3 (pt) |
| PL (1) | PL1838341T3 (pt) |
| WO (1) | WO2006078213A1 (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2719397A1 (en) * | 2006-06-12 | 2014-04-16 | GlaxoSmithKline Biologicals SA | Use of alpha-toxin for treating and preventing staphylococcus infections |
| JP2008013447A (ja) * | 2006-07-03 | 2008-01-24 | Juntendo | 毒素検出方法 |
| US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
| AU2008292897B2 (en) | 2007-08-31 | 2015-01-22 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| US8758765B2 (en) | 2008-07-29 | 2014-06-24 | The University Of Chicago | Compositions and methods related to Staphylococcal bacterium proteins |
| PT3281947T (pt) | 2009-04-03 | 2020-05-07 | Univ Chicago | Composições e métodos relacionados com variantes da proteína a (spa) |
| EP2588120B1 (en) | 2010-07-02 | 2017-11-15 | The University of Chicago | Compositions and methods related to protein a (spa) variants |
| US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
| CN102993278B (zh) * | 2012-09-29 | 2014-02-19 | 重庆原伦生物科技有限公司 | 耐甲氧西林金黄色葡萄球菌(MRSA)疫苗重组蛋白抗原FnbA1的纯化方法 |
| CA2900008C (en) | 2013-02-07 | 2025-10-07 | Children's Medical Center Corporation | PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE |
| CN106680483A (zh) * | 2015-11-06 | 2017-05-17 | 中创云牧(内蒙古)科技咨询有限公司 | 金黄色葡萄球菌黏附素蛋白抗体的抗黏附能力的检测方法 |
| CA3015639A1 (en) * | 2016-03-09 | 2017-09-14 | Technion Research And Development Foundation Ltd. | Liposomal formulations and methods of using same in agriculture |
| CA3081436A1 (en) * | 2017-10-31 | 2019-05-09 | Western Oncolytics Ltd. | Platform oncolytic vector for systemic delivery |
| US20210206857A1 (en) * | 2018-05-21 | 2021-07-08 | Bioprocessia Technologies Llc | Multivalent protein complexes |
| BR112021022902A2 (pt) | 2019-05-14 | 2022-01-25 | Univ Chicago | Métodos e composições que compreendem variantes de proteína a staphylococcus (spa) |
| WO2021051136A1 (en) | 2019-09-13 | 2021-03-18 | The University Of Chicago | Methods and compositions for treating staphylococcal infections |
| TW202227621A (zh) | 2020-11-19 | 2022-07-16 | 美商凱立凡爾免疫治療股份有限公司 | 重塑腫瘤微環境的溶瘤免疫療法 |
| MX2023012608A (es) | 2021-04-30 | 2023-11-03 | Kalivir Immunotherapeutics Inc | Virus oncoliticos para la expresion modificada del mhc. |
| SE2200142A1 (en) * | 2022-12-13 | 2024-06-14 | Savacc Ab | Chrisvacc |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US5540933A (en) | 1985-05-31 | 1996-07-30 | La Jolla Cancer Research Foundation | Isolation and use of fibronectin receptor |
| EP0231039B1 (en) | 1986-01-14 | 1992-01-08 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Process for preparing immunological complexes and pharmaceutical composition containing these complexes |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| EP0444174A4 (en) * | 1989-09-08 | 1992-09-16 | Wisconsin Alumni Research Foundation | Test for the detection of staphylococcal fibronectin-receptor antibodies |
| NL9000207A (pt) * | 1990-01-29 | 1991-08-16 | Duphar Int Res | |
| US5270168A (en) * | 1990-02-21 | 1993-12-14 | Board Of Regents, The University Of Texas System | Method for diagnosing non-healing ulcers |
| NL9002314A (nl) | 1990-10-23 | 1992-05-18 | Nederlanden Staat | Immunogene complexen, in het bijzonder iscoms. |
| US5618916A (en) | 1993-01-06 | 1997-04-08 | The Jewish Hospital Of St. Louis | Purified protein which functions as a mycobacterial receptor for fibronectin |
| CA2185097A1 (en) | 1994-03-09 | 1995-09-14 | Pacific Biotech International, Inc. | Activating virus |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US20010053365A1 (en) * | 1995-04-25 | 2001-12-20 | Smithkline Beecham Biologicals S.A. | Vaccines |
| US5753235A (en) | 1996-02-15 | 1998-05-19 | Heska Corporation | Recombinant canine herpesviruses |
| SE9600647D0 (sv) | 1996-02-21 | 1996-02-21 | Bror Morein | Ny användning |
| EP0950068B1 (en) * | 1996-05-16 | 2005-11-09 | THE TEXAS A&M UNIVERSITY SYSTEM | Collagen binding protein compositions and methods of use |
| DK0835930T3 (da) | 1996-10-09 | 2001-06-18 | Akzo Nobel Nv | Europæiske vaccinestammer af porcint reproduktions- og respirationssyndrom-virus. (PRRSV) |
| US6231859B1 (en) | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
| US6685943B1 (en) * | 1997-01-21 | 2004-02-03 | The Texas A&M University System | Fibronectin binding protein compositions and methods of use |
| AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
| US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
| SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
| WO2004030696A2 (en) | 2002-10-02 | 2004-04-15 | Nordic Vaccine Technology A/S | Composition for vaccination |
| SE0300795D0 (sv) | 2003-03-24 | 2003-03-24 | Isconova Ab | Composition comprising iscom particles and live micro-organisms |
| SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
-
2006
- 2006-01-20 BR BRPI0606481-7A patent/BRPI0606481A2/pt not_active Application Discontinuation
- 2006-01-20 DK DK06701328.4T patent/DK1838341T3/da active
- 2006-01-20 CN CN200680002650.3A patent/CN101107009B/zh not_active Expired - Lifetime
- 2006-01-20 ES ES06701328T patent/ES2433467T3/es not_active Expired - Lifetime
- 2006-01-20 WO PCT/SE2006/000082 patent/WO2006078213A1/en not_active Ceased
- 2006-01-20 CA CA2592627A patent/CA2592627C/en not_active Expired - Lifetime
- 2006-01-20 EP EP06701328.4A patent/EP1838341B1/en not_active Expired - Lifetime
- 2006-01-20 PL PL06701328T patent/PL1838341T3/pl unknown
- 2006-01-20 US US11/795,662 patent/US8007806B2/en active Active
-
2011
- 2011-07-20 US US13/186,961 patent/US8187585B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| PL1838341T3 (pl) | 2014-04-30 |
| ES2433467T3 (es) | 2013-12-11 |
| CA2592627A1 (en) | 2006-07-27 |
| US8007806B2 (en) | 2011-08-30 |
| CN101107009B (zh) | 2014-08-06 |
| US8187585B2 (en) | 2012-05-29 |
| EP1838341B1 (en) | 2013-08-14 |
| US20090208562A1 (en) | 2009-08-20 |
| CN101107009A (zh) | 2008-01-16 |
| WO2006078213A1 (en) | 2006-07-27 |
| DK1838341T3 (da) | 2013-11-04 |
| CA2592627C (en) | 2014-02-25 |
| US20110303563A1 (en) | 2011-12-15 |
| EP1838341A1 (en) | 2007-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0606481A2 (pt) | composição de vacina compreendendo uma proteìna de ligação a fibronectina ou um peptìdeo de ligação a fibronectina | |
| CY1124802T1 (el) | Δεσμευτικοι παραγοντες σκληροστινης | |
| BR112012014801A8 (pt) | uso combinado de proteínas cry1ca e cry1fa para controle de resistência a insetos | |
| ECSP088758A (es) | Métodos para reducir la aglomeración de proteína | |
| AR056397A1 (es) | Composicion inmunogenica | |
| BRPI0514340A (pt) | formulações de estabilização | |
| NO20081127L (no) | Vaksinering mot Dengue virusinfeksjon | |
| BRPI1013688A8 (pt) | Proteínas de ligação de il-17. | |
| CL2011000206A1 (es) | Composicion biocida que comprende ciprodinil y fluazinam; metodo para controlar enfermedades, en plantas utiles o en material de propagacion, causadas por fitopatogenos (div. sol. n°2602-06). | |
| ECSP099678A (es) | Composiciones de carne de pescados y mariscos que comprenden productos de proteina estructurada | |
| EA201001223A1 (ru) | Стабилизированные белковые композиции | |
| BR122021020829B8 (pt) | Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada | |
| BRPI0615265A8 (pt) | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos | |
| MX348432B (es) | Epitopes. | |
| BRPI0615792A2 (pt) | métodos de controle de pestes com base no uso de rnai | |
| BRPI0911482A2 (pt) | Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer | |
| BRPI0715396B8 (pt) | método de produção de uma composição para vacina | |
| BRPI0819092A2 (pt) | Evolução direcionada usando proteínas que compreendem aminoácidos não naturais. | |
| WO2006094093A3 (en) | A method for identifying skin care composition-resistant skin-binding peptides | |
| BRPI0620125A8 (pt) | método para regulação de redução da função biológica de uma proteína, molécula de ocorrência não natural, vetor recombinante, e método para isolar uma protéina de uma amostra | |
| WO2009123764A3 (en) | Compositions and use of epas1 inhibitors | |
| BRPI0511482A (pt) | incorporação sìtio-especìfica de aminoácidos artificiais contendo átomos pesados em proteìnas para determinação de estrutura cristalina | |
| EP2081029A3 (en) | Bio-markers for diagnosing diabetic retinopathy | |
| BR112013000840A2 (pt) | método para aumentar o efeito de forma ativada potencializada de anticorpo para molécula endógena biológica, composição farmacêutica e uso de combinação de molécula biológica endógena com forma ativada potencializada de anticorpo para a sintase no endotelial. | |
| CL2008001719A1 (es) | Compuestos derivados de [1,10]-fenantrolina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades neurodegenerativas o hematologicas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |